April 27th 2024
Targeted therapies and immunotherapies across the ovarian, endometrial, and cervical cancers landscape play expanded roles, according to Ritu Salani, MD, MBA.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Rucaparib Produces High Response Rates in Heavily Pretreated Ovarian Cancer
October 11th 2016The majority of heavily pretreated patients with high-grade ovarian cancer (HGOV) and germline or somatic <em>BRCA</em> mutations showed a durable response to rucaparib, according to findings from an analysis of two phase II trials.
Read More
Niraparib is a Breakthrough for Patients With Ovarian Cancer, Expert Says
October 8th 2016Maintenance therapy with the PARP1/2 inhibitor niraparib reduced the risk of progression or death by 73% compared with placebo for patients with germline <em>BRCA</em>-positive platinum-sensitive, recurrent ovarian cancer, according to findings from the phase III NOVA trial.
Read More
When to Perform a Prophylactic Bilateral Oophorectomy in Ovarian Cancer
October 7th 2016Maurie Markman, MD, president of Medicine and Science, Eastern Regional Medical Center, discusses when to perform a prophylactic bilateral oophorectomy on a patient who does not have ovarian cancer, but has a known BRCA mutation.
Watch
Pembrolizumab Produces Promising Antitumor Activity in Cervical Cancer Study
October 3rd 2016According to results from a phase Ib study, pembrolizumab (Keytruda) was well tolerated and demonstrated promising antitumor activity in patients with PD-L1–positive advanced cervical squamous cell cancer.
Read More
Fewer GI, GU Toxicities Reported With Postoperative Pelvic IMRT in Endometrial, Cervical Cancer
October 1st 2016According to findings from a randomized phase III trial, patients with endometrial and cervical cancer reported significantly less acute gastrointestinal toxicity (GI) when treated with pelvic intensity-modulated radiation therapy (IMRT) as opposed to standard pelvic radiation therapy.
Read More
Metformin Shows Positive Results in Endometrial Cancer
September 26th 2016Findings from a recent phase II trial<sup>1 </sup>showed that combining the diabetes drug metformin with everolimus (Afinitor) and letrozole resulted in a clinical benefit rate (CBR) of 60% in women with advanced or recurrent endometrioid endometrial cancer.
Read More
FDA Gives Niraparib Fast Track Designation for Ovarian Cancer
September 19th 2016Niraparib has been granted a fast track designation by the FDA as a treatment for women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer, the company developing the PARP inhibitor, Tesaro, has announced.
Read More
Rio Grande Urology Partners With Gynecologic Oncologist
September 7th 2016As a group, Rio Grande Urology shares a sense of obligation and culture. Its leaders have embraced an integrative model approach and sees the advantages of it. It was formed by 4 urology practices merging to build a main campus that houses the cancer center and radiation therapy center.
Read More
Rucaparib Granted Priority Review for Ovarian Cancer
August 24th 2016Priority review has been granted by the FDA for a new drug application (NDA) for rucaparib as a treatment for patients with <em>BRCA</em>-positive advanced ovarian cancer who have received at least 2 prior lines of chemotherapy, according to Clovis, the manufacturer of the PARP inhibitor.
Read More
The Benefits and Risks of Bilateral Salpingo-Oophorectomy in the Treatment of Ovarian Cancer
August 10th 2016Maurie Markman, MD, president, Medicine and Science, Cancer Treatment Centers of America, discusses the benefits and risks of performing a bilateral salpingo-oophorectomy as a treatment for patients with ovarian cancer.
Watch
Cobas HPV Test With SurePath is Approved by FDA
July 12th 2016The FDA has approved the cobas HPV Test for use with SurePath Preservative Fluid for the detection of human papilloma virus in cervical cells. SurePath is one of the two approved liquid collection fluids commonly used for Pap tests.
Read More
Novel FGFR Inhibitor Shows Promise in Cholangiocarcinoma
July 8th 2016Treatment with ARQ-087 demonstrated promising signs of clinical activity with a manageable safety profile for patients with FGFR2 fusion-positive advanced and/or metastatic intrahepatic cholangiocarcinoma, according to findings from an ongoing phase I/II study presented at the 2016 World Congress on Gastrointestinal Cancer.
Read More
The Importance of Multi-Gene Panel Testing for BRCA Mutations
July 1st 2016Allison W. Kurian, MD, MSc, associate professor of Medicine and of Health Research and Policy, Stanford University School of Medicine, discusses two ongoing trials utilizing multi-gene panels to uncover previously undetected risks in patients with breast and ovarian cancer.
Watch
INO-VATE Updated Results Confirm PFS Benefit in Relapsed/Refractory ALL
June 14th 2016The anti-CD22 antibody-drug conjugate inotuzumab ozogamicin demonstrated significantly improved progression-free survival (PFS) and complete remission (CR) rates compared with chemotherapy for patients with relapsed or refractory acute lymphoblastic leukemia (ALL).
Read More
Novel Angiogenesis Inhibitor Shows Preliminary Evidence of Activity
June 10th 2016A novel dual-pathway inhibitor of tumor angiogenesis passed a preliminary clinical test, demonstrating manageable toxicity and biomarker evidence of engagement with the drug's targets, as reported at the 2016 ASCO Annual Meeting in Chicago.
Read More
CAR Therapy Yields High Complete Response Rates in Adults with B-cell ALL in Phase I Trial
June 9th 2016Infusion with 19-28z chimeric antigen receptor (CAR) modified T-cells led to complete response (CR) rates of 77% to 90% and minimal residual disease (MRD)-CR rates of 68% to 70% in adult patients with relapsed or refractory B-cell acute lymphocytic leukemia (B-ALL).
Read More
Large Database Study Finds 11 Genes Associated with Increased Ovarian Cancer Risk
June 9th 2016The largest-ever genetic analysis of ovarian cancer patients yielded a short list of 11 suspect germline genetic mutations that may be associated with an increased risk for developing ovarian cancer, according to an oral presentation at the 2016 ASCO Annual Meeting in Chicago.
Read More